Johnson & Johnson (JNJ) AGM 2025 summary

Opening remarks and agenda

• The meeting opened with a welcome, cautionary statements on forward-looking information, and an overview of the agenda, including business updates, voting items, and a Q&A session.

Financial performance review

• Operational sales growth reached 7% in 2024, with adjusted net earnings of $24.2 billion and free cash flow of approximately $20 billion.

• Innovative Medicine reported $57 billion in annual sales, with Darzalex exceeding $3 billion in a single quarter and Spravato reaching $1 billion annually.

• MedTech sales surpassed $30 billion for the second consecutive year, with strong cardiovascular momentum.

Board and executive committee updates

• Two directors, Scott Davis and Anne Mulcahy, retired during the year and were recognized for their service.

• The board and executive committee, along with independent auditors, were present for the meeting.